Get the Stockscreener App
132.55
46.66%
42.17
After Hours:
132.53
-0.02
-0.02%
Apogee Therapeutics Inc stock is traded at $132.55, with a volume of 61.25M.
It is up +46.66% in the last 24 hours and up +63.32% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$90.38
Open:
$132.6
24h Volume:
61.25M
Relative Volume:
32.18
Market Cap:
$9.99B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-30.63
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
+53.79%
1M Performance:
+63.32%
6M Performance:
+69.94%
1Y Performance:
+215.90%
1-Day Range:
$132.45
$133.00
1-Week Range:
$84.01
$133.00
52-Week Range:
$34.34
$133.00
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
132.55 | 6.81B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
APGE Stock Climbs As Zumilokibart Data And Blackstone Deal Reprice The Story - timothysykes.com
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? - The Motley Fool
Form 144 APOGEE THERAPEUTICS INC For: 22 June By Investing.com - Investing.com Canada
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer - Yahoo Finance
The $11 Billion Reason Abbvie Stock Is Up Today - Barchart.com
APGE (NASDAQ: APGE) files Form 144 listing recent 10b5-1 sales - Stock Titan
Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders? - Finviz
APGE Stock Surges As Street Backs Zumilokibart Breakout - StocksToTrade
AbbVie (ABBV) Acquires Apogee Therapeutics for $10.9 Billion - GuruFocus
Apogee Therapeutics, Inc. Stock 12‑Month Price Target Cut to $119.07, Implies 32% Upside - TradingView
Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising - Barron's
APGE Stock Jumps As Blackstone Deal Backs Breakout Trial Data - timothysykes.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE) - PR Newswire
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Expanding Immunology Pipeline with Breakthrough Dermatology and Respiratory Treatments - Minichart
APGE Stock Surges On Trial Win And $1.3B Blackstone Deal - StocksToTrade
AbbVie up 7% amid Apogee Therapeutics $10.9B deal - Breakingthenews.net
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
AbbVie (ABBV) Is Buying Apogee Therapeutics For $10.9 Billion - Yahoo Finance
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday - Benzinga
Crude Oil Falls Over 2%; Getty Images Shares Spike Higher - Benzinga
Form 144 Apogee Therapeutics For: 22 June By Investing.com - Investing.com South Africa
Citigroup Downgrades Apogee Therapeutics to Neutral From Buy, Price Target is $135 - marketscreener.com
As AbbVie eyes Apogee, these biotech stocks earn the highest quant ratings - MSN
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJ
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders - PR Newswire
AbbVie deepens immunology legacy in $10.9bn Apogee buyout - Yahoo Finance
APGE Stock Extends Run As Street Backs Zumilokibart - timothysykes.com
Wedbush Downgrades Apogee Therapeutics to Neutral From Outperform, Price Target is $135 - marketscreener.com
AbbVie Inc. (ABBV) Announces Acquisition of Apogee Therapeutics - GuruFocus
AbbVie sharpens immunology focus with $10.9 billion Apogee deal - Reuters
ABBV Acquires Apogee Therapeutics for $10.9 Billion to Boost Imm - GuruFocus
APGE Downgraded by Canaccord Genuity -- Price Target Raised to $135.11 - GuruFocus
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Expand Immunology Pipeline - GuruFocus
AbbVie acquires Apogee Therapeutics in $10.9B deal - grafa.com
Michael Henderson to sell 80,000 shares of Charles Schwab (APGE) - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover - TechStock²
AbbVie (ABBV) to Acquire Apogee Therapeutics (APGE) for $10.9 Bi - GuruFocus
AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal - The Boston Globe
Apogee Therapeutics signs antibody discovery and license agreements with Paragon - Investing.com Australia
Apogee Therapeutics stock hits all-time high at 132.61 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock hits all-time high at 132.61 USD - Investing.com UK
APGE Stock Climbs As Wall Street Bets On Zumilokibart - StocksToTrade
AbbVie to acquire Apogee Therapeutics in $10.9B deal - Yahoo Finance
AbbVie (ABBV) Set to Acquire Apogee Therapeutics (APGE) for $11 Billion - GuruFocus
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal - marketscreener.com
Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal - Law360
AbbVie seals $10.9B deal to acquire Waltham biotech Apogee Therapeutics - The Business Journals
AbbVie (ABBV) Set to Acquire Apogee Therapeutics for $10.9 Billi - GuruFocus
APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Canaccord Genuity Downgrades Apogee Therapeutics to Hold From Buy, Adjusts Price Target to $135.11 From $130 - marketscreener.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):